{"id":"NCT04523129","sponsor":"Novaliq GmbH","briefTitle":"ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)","officialTitle":"A Phase 3, Multi-center, Randomized, Double-masked, Vehicle-controlled Clinical Trial to Assess the Efficacy and Safety of Topical CyclASolÂ® for the Treatment of Dry Eye Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-12-05","primaryCompletion":"2021-09-03","completion":"2021-10-08","firstPosted":"2020-08-21","resultsPosted":"2023-03-10","lastUpdate":"2023-03-10"},"enrollment":834,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Disease"],"interventions":[{"type":"DRUG","name":"CyclASol topical ocular, eye drops","otherNames":["Ciclosporine (CSA)"]},{"type":"DRUG","name":"Vehicle topical ocular, eye drops","otherNames":["Vehicle"]}],"arms":[{"label":"CyclASol Ophthalmic Solution","type":"EXPERIMENTAL"},{"label":"Vehicle Ophthalmic solution","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this pivotal trial is to assess the efficacy, safety and tolerability of CyclASol in comparison to the vehicle for the treatment of signs and symptoms of Dry Eye Disease (DED).","primaryOutcome":{"measure":"Change From Baseline in Total Corneal Fluorescein Staining","timeFrame":"baseline and 1 month [day 29]","effectByArm":[{"arm":"CyclASol Ophthalmic Solution","deltaMin":-3.96,"sd":0.146},{"arm":"Vehicle Ophthalmic Solution","deltaMin":-3.55,"sd":0.149}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":13},"locations":{"siteCount":27,"countries":["United States"]},"refs":{"pmids":["37022717"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":423},"commonTop":["Instillation Site Pain"]}}